ROSALIND™ is a simulation platform designed to provide better personalized treatment options based on the genetic profile of the patient’s cancer.

The platform is driven by a dynamic, programmable computer simulation of how cell signaling pathways are altered by certain gene mutations that are associated with specific types of cancers. The impact of thousands of different drug combinations on these mutated pathways are then evaluated in silico. The underlying technology produces a comprehensive mathematical model of cell signaling and identifies optimal personalized cancer treatment options for consideration by the patient’s oncologist.

ROSALIND is presently in the experimental phase of development and is undergoing validation testing.

Home page of this offering   provided by Cotinga Pharmaceuticals